ES2163504T3 - Formas de dosificacion de liberacion controlada de azitromicina. - Google Patents

Formas de dosificacion de liberacion controlada de azitromicina.

Info

Publication number
ES2163504T3
ES2163504T3 ES95913923T ES95913923T ES2163504T3 ES 2163504 T3 ES2163504 T3 ES 2163504T3 ES 95913923 T ES95913923 T ES 95913923T ES 95913923 T ES95913923 T ES 95913923T ES 2163504 T3 ES2163504 T3 ES 2163504T3
Authority
ES
Spain
Prior art keywords
controlled
azitromycin
release
dosage forms
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913923T
Other languages
English (en)
Other versions
ES2163504T5 (es
Inventor
William J Curatolo
Hylar L Friedman
Richard W Korsmeyer
Mott Steven R Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22900590&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2163504(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES2163504T3 publication Critical patent/ES2163504T3/es
Application granted granted Critical
Publication of ES2163504T5 publication Critical patent/ES2163504T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Detergent Compositions (AREA)

Abstract

FORMULA DE DOSIFICACION CON ADMINISTRACION CONTROLADA DE AZITROMICINA CON UN MEJOR PERFIL DE EFECTOS SECUNDARIOS; PROCESO PARA PREPARAR LA FORMULA DE DOSIFICACION; Y UN METODO PARA TRATAR UNA INFECCION MICROBIANA, QUE INCLUYE LA ADMINISTRACION DE AZITROMICINA DOSIFICADA DE FORMA CONTROLADA A UN MAMIFERO, INCLUIDO EL SER HUMANO, QUE NECESITE ESTE TRATAMIENTO.
ES95913923T 1994-05-06 1995-04-13 Formas de dosificacion de liberacion controlada de azitromicina. Expired - Lifetime ES2163504T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23909494A 1994-05-06 1994-05-06
US239094 1994-05-06

Publications (2)

Publication Number Publication Date
ES2163504T3 true ES2163504T3 (es) 2002-02-01
ES2163504T5 ES2163504T5 (es) 2008-05-16

Family

ID=22900590

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913923T Expired - Lifetime ES2163504T5 (es) 1994-05-06 1995-04-13 Formas de dosificacion de liberacion controlada de azitromicina.

Country Status (42)

Country Link
US (2) US6068859A (es)
EP (1) EP0758244B2 (es)
JP (1) JP2977907B2 (es)
KR (1) KR100232297B1 (es)
CN (1) CN1096862C (es)
AP (1) AP548A (es)
AT (1) ATE209497T1 (es)
AU (1) AU680356B2 (es)
BG (1) BG63152B1 (es)
BR (1) BR9501929A (es)
CA (1) CA2189658C (es)
CO (1) CO4290346A1 (es)
CZ (1) CZ292360B6 (es)
DE (1) DE69524214T3 (es)
DK (1) DK0758244T4 (es)
DZ (1) DZ1880A1 (es)
ES (1) ES2163504T5 (es)
FI (1) FI964452A0 (es)
HR (1) HRP950277B1 (es)
HU (1) HUT77530A (es)
IL (3) IL113516A (es)
IS (1) IS4282A (es)
LV (1) LV11729B (es)
MA (1) MA23537A1 (es)
MX (1) MX9605419A (es)
MY (1) MY113059A (es)
NO (1) NO315453B1 (es)
NZ (1) NZ283160A (es)
OA (1) OA10320A (es)
PE (1) PE4796A1 (es)
PL (1) PL179910B1 (es)
PT (1) PT758244E (es)
RO (1) RO114740B1 (es)
RU (1) RU2130311C1 (es)
SI (1) SI9520049A (es)
SK (1) SK282854B6 (es)
TN (1) TNSN95051A1 (es)
TW (1) TW420616B (es)
UA (1) UA41995C2 (es)
UY (1) UY23958A1 (es)
WO (1) WO1995030422A1 (es)
ZA (1) ZA953627B (es)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914132A (en) * 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5605889A (en) 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
KR100232297B1 (ko) * 1994-05-06 1999-12-01 디. 제이. 우드 아지트로마이신의 제어된 방출 투여형 제제
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
HRP970493A2 (en) * 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
WO1998022096A1 (en) * 1996-11-15 1998-05-28 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6551616B1 (en) 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
TWI235068B (en) * 1998-03-26 2005-07-01 Fujisawa Pharmaceutical Co Sustained-release pharmaceutical composition
ES2229783T3 (es) * 1998-06-03 2005-04-16 Alza Corporation Dispositivos para proporcionar una terapia faramaceutica prolongada.
DE19850445A1 (de) * 1998-11-02 2000-05-04 Falk Pharma Gmbh Arzneimittel zur topischen Behandlung entzündlicher Darmerkrankungen
ES2310164T3 (es) * 1999-02-10 2009-01-01 Pfizer Products Inc. Dispositivo de liberacion controlada por la matriz.
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6878386B1 (en) * 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
BR0013719A (pt) * 1999-09-02 2002-07-23 Nostrum Pharmaceuticals Inc Dosagem oral de liberaçâo controlada, apropriada para administração oral
NZ518281A (en) * 1999-12-23 2005-01-28 Pfizer Prod Inc Controlled release drug dosage core comprising a drug-containing composition and a water-swellable composition
CA2395231C (en) 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
IL135061A0 (en) * 2000-03-14 2001-05-20 Ahron Jodaikin Strategic targeted fluoridation and chemical treatment of teeth
US20050175959A1 (en) * 2000-03-14 2005-08-11 Coll Partners Ltd. System for the controlled delivery of an active material to a dental site
US6569152B2 (en) 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
FR2811571B1 (fr) * 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
EP1313473A2 (en) 2000-08-30 2003-05-28 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
GB0025208D0 (en) * 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
US6946146B2 (en) * 2001-04-18 2005-09-20 Nostrum Pharmaceuticals Inc. Coating for a sustained release pharmaceutical composition
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
EP1671979B1 (en) 2001-05-22 2008-08-13 Pfizer Products Inc. New Cristal Form of Azithromycin
US20080305173A1 (en) * 2001-07-31 2008-12-11 Beuford Arlie Bogue Amorphous drug beads
GEP20063812B (en) * 2001-08-21 2006-05-10 Pfizer Prod Inc Single dose azithromycin for treating respirator infections
US6673369B2 (en) * 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
EP1541134A3 (en) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Stabilized azithromycin compositions
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US20030152624A1 (en) * 2001-12-20 2003-08-14 Aldrich Dale S. Controlled release dosage form having improved drug release properties
EP1455758A1 (en) * 2001-12-21 2004-09-15 Pfizer Products Inc. Directly compressible formulations of azithromycin
WO2003053399A2 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Methods for wet granulating azithromycin
BR0307331A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
CA2472028C (en) 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
KR100758045B1 (ko) * 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
ATE407674T1 (de) * 2002-04-09 2008-09-15 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
GB0214013D0 (en) * 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US8980870B2 (en) * 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP2006507298A (ja) * 2002-10-30 2006-03-02 ファルマシア コーポレーション 経口持続放出型錠剤、ならびにその製造法および使用法
US7811605B2 (en) * 2002-11-06 2010-10-12 Uluru Inc. Method of formation of shape-retentive aggregates of gel particles and their uses
US7351430B2 (en) * 2002-11-06 2008-04-01 Uluru Inc. Shape-retentive hydrogel particle aggregates and their uses
US7670627B2 (en) * 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
MEP10808A (en) 2002-12-16 2010-06-10 Kissei Pharmaceutical Solid drug for oral use
EP1589951B1 (en) * 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
FR2850577B1 (fr) * 2003-02-03 2005-04-15 Ethypharm Sa Particules enrobees a gout masque, leur procede de preparation et comprimes orodispersibles contenant lesdites particules
BRPI0410098A (pt) * 2003-05-06 2006-05-16 Nirmal Mulye formulação de liberação controlada de derivados de eritromicina
US7063862B2 (en) 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
EP1638529B1 (en) * 2003-06-16 2016-08-10 ANDRX Pharmaceuticals, LLC. Oral extended-release composition
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
WO2005009365A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005009368A2 (en) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2005041838A (ja) * 2003-07-24 2005-02-17 Matsumoto Shika Univ バイオフィルム除去剤
US20050025829A1 (en) * 2003-07-29 2005-02-03 Kim Cherng-Ju Controlled drug release tablets
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8758820B2 (en) 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
CA2535398C (en) * 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
AU2004270170B2 (en) 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
BRPI0417360A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc método para a preparação de multiparticulados farmacêuticos
JP2007513146A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 液体系プロセスによるアジスロマイシンマルチパーティキュレート剤形
BRPI0417348A (pt) * 2003-12-04 2007-03-13 Pfizer Prod Inc processo de gelatinização por spray com utilização de uma extrusora para preparação de composições de droga cristalina multiparticulada contendo preferencialmente um poloxámero e um glicerìdeo
KR20060109481A (ko) * 2003-12-04 2006-10-20 화이자 프로덕츠 인코포레이티드 바람직하게는 폴록사머와 글리세라이드를 함유하는다미립자 아지트로마이신 조성물의 제조를 위해 압출기를사용하는 분무응결 방법
WO2005053654A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release dosage forms of azithromycin
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
EP1691786A1 (en) * 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
US20040224019A1 (en) * 2004-03-03 2004-11-11 Adi Shefer Oral controlled release system for targeted drug delivery into the cell and its nucleus for gene therapy, DNA vaccination, and administration of gene based drugs
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
WO2005120585A1 (en) * 2004-06-04 2005-12-22 Case Western Reserve University Dual function polymer micelles
US20070224269A1 (en) * 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
AU2005269981A1 (en) 2004-07-02 2006-02-09 Bonck, John A Tablet for pulsed delivery
EP2801354B1 (en) 2004-10-08 2017-02-08 Forward Pharma A/S Controlled release pharmaceutical compositions comprising a fumaric acid ester
EP1830815A1 (en) * 2004-12-21 2007-09-12 Pfizer Products Incorporated Enteric coated azithromycin multiparticulates
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US10071060B2 (en) * 2005-07-08 2018-09-11 Bioventures, Llc Asymmetrically coated table
US8858993B2 (en) * 2005-07-25 2014-10-14 Metrics, Inc. Coated tablet with zero-order or near zero-order release kinetics
EP1749519A1 (de) * 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CA2634830A1 (en) * 2005-12-27 2007-07-05 Labopharm Inc. Degradable polymeric microsphere composition
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US20070243248A1 (en) * 2006-04-14 2007-10-18 Cherukuri S Rao Rapidly disintegrating solid oral dosage form of liquid dispersions
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
JP2009539866A (ja) * 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
US7713549B2 (en) * 2006-06-30 2010-05-11 Board Of Trustees Of The University Of Arkansas Extended release perforated tablet
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US7910135B2 (en) * 2006-10-13 2011-03-22 Uluru Inc. Hydrogel wound dressing and biomaterials formed in situ and their uses
US20110052688A1 (en) * 2006-11-21 2011-03-03 San-Laung Chow Solid dispersion composition
EP2091519B1 (en) * 2006-11-30 2015-06-24 Bend Research, Inc Multiparticulates of spray-coated drug and polymer on a meltable core
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
CN100441196C (zh) * 2006-12-15 2008-12-10 北京化工大学 一种制备微粉化阿奇霉素的方法
WO2008109018A1 (en) * 2007-03-02 2008-09-12 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US20080228268A1 (en) * 2007-03-15 2008-09-18 Uluru, Inc. Method of Formation of Viscous, Shape Conforming Gels and Their Uses as Medical Prosthesis
BRPI0700969A (pt) * 2007-03-22 2008-11-04 Ouro Fino Participacoes E Empr composição para o tratamento de afecções bacterianas e inflamatórias em animais de companhia
US7850453B2 (en) * 2007-08-08 2010-12-14 Coll Partners Ltd. Reshapable device for fixation at a dental site
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
US20100197586A1 (en) 2007-09-11 2010-08-05 Dorian Bevec Use of secretin and optionally urodilatin as therapeutic agents
WO2009033724A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
JP2010539037A (ja) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのペプチドの使用
CA2698985A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
RU2010113977A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение антагониста рецептора фибриногена и/или пептид фолликулярного гонадолиберина в качестве терапевтического средства при лечении инфекции streptococcus pneumoniae
WO2009033731A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a laminin peptide as a therapeutic agent
RU2010114011A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Терапевтическое применение пептида yglf и сочетания с kvlpvpq
RU2010114052A (ru) 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Применение пептида в качестве терапевтического средства
KR20100058555A (ko) 2007-09-11 2010-06-03 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｂｐｐ－ｂ의 용도
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
EP2198859A1 (en) * 2008-12-17 2010-06-23 Losan Pharma GmbH Melt-coated pharmaceutical composition with fast release
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
EP2498764B1 (en) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmented hydrogels
WO2011113507A2 (en) 2010-03-15 2011-09-22 Ulrich Dietz Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
WO2011125075A2 (en) 2010-04-08 2011-10-13 Fdc Limited A novel gastroretentive delivery of macrolide
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
PE20131126A1 (es) 2010-09-02 2013-10-21 Gruenenthal Chemie Forma de dosificacion resistente a alteracion que comprende un polimero anionico
US8709310B2 (en) 2011-01-05 2014-04-29 Hospira, Inc. Spray drying vancomycin
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
DK2741766T3 (en) * 2011-08-08 2016-01-11 Aptalis Pharma Ltd Process for dissolving solid compositions containing digestive enzymes
US10653631B2 (en) 2011-09-07 2020-05-19 Roland SAUR-BROSCH Optimal colon targeting technology
JP2014529630A (ja) * 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
WO2013103801A1 (en) * 2012-01-04 2013-07-11 Hospira, Inc. Pharmaceutical spray drying
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
WO2014031676A1 (en) * 2012-08-20 2014-02-27 O-Ray Pharma, Inc. Process for manufacturing drug delivery formulations
CN103860515A (zh) * 2012-12-10 2014-06-18 中国科学院上海药物研究所 阿奇霉素渗透泵控释片及其制备方法
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
JP6041823B2 (ja) * 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US9668844B2 (en) 2013-11-06 2017-06-06 Colldent Y.A Ltd Device for fixation at a dental site
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
EP3307275B1 (en) * 2015-06-10 2021-05-26 Piedmont Animal Health Inc. Injectable antibiotic formulations and use thereof
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
WO2018190621A1 (ko) * 2017-04-10 2018-10-18 성균관대학교 산학협력단 다공성 위체류층을 포함하는 서방성 제제 및 이의 제조방법
EP4041285A4 (en) 2019-10-11 2023-10-11 Anatara Lifesciences Limited GASTROINTESTINAL HEALTH COMPOSITION
CN112326838A (zh) * 2020-11-10 2021-02-05 湖北省宏源药业科技股份有限公司 一种改善阿奇霉素胶囊溶出曲线的测定方法
CN113116859B (zh) * 2021-04-12 2022-08-30 海南普利制药股份有限公司 阿奇霉素丸芯包衣制剂
CN113985783B (zh) * 2021-10-29 2022-09-02 中山东菱威力电器有限公司 一种冰激淋料浆有无检测电路

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4340582A (en) * 1981-01-15 1982-07-20 Abbott Laboratories Erythromycin base tablets
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4434153A (en) * 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
PH19293A (en) * 1982-11-15 1986-03-04 Pfizer Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4496322A (en) 1983-05-11 1985-01-29 University Of Toronto Innovations Foundation Benzoin antimicrobial dental varnishes
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
ES2029851T3 (es) 1986-04-17 1992-10-01 Eltech Systems Corporation Electrodo con catalizador de platino en una pelicula superficial y utilizacion del mismo.
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
IT1222309B (it) 1987-07-08 1990-09-05 Menarini Sas Utilizzazione di forme farmaceutiche per uso topico contenenti miocamicina per la terapia delle infezione da germi sensibili alla miocamicina stessa
RU2066324C1 (ru) 1987-07-09 1996-09-10 Пфайзер Инк. Кристаллический дигидрат азитромицина и способ его получения
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
EP0458887A1 (en) * 1989-02-16 1991-12-04 Btg International Limited Dispensing device
CA2021282C (en) * 1989-07-18 1994-11-29 Anthony L. Kuczynski Dispenser comprising ionophore
US5173299A (en) 1989-11-17 1992-12-22 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5084267A (en) 1989-11-17 1992-01-28 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5230895A (en) 1990-05-01 1993-07-27 Copley Pharmaceutical Inc. Sustained released delivery system for use in the periodontal pocket
CA2082398C (en) * 1990-05-14 2004-06-29 Gary R. Jernberg Surgical implant and method incorporating chemotherapeutic agents
US5114718A (en) 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
SE9201930D0 (sv) * 1992-06-24 1992-06-24 Astra Ab Gastric antibacterial treatment
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
EP0670717B1 (en) 1992-11-30 1998-11-25 Pfizer Inc. Supported liquid membrane delivery devices
WO1995009601A1 (en) * 1993-10-01 1995-04-13 The Procter & Gamble Company Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
KR100232297B1 (ko) * 1994-05-06 1999-12-01 디. 제이. 우드 아지트로마이신의 제어된 방출 투여형 제제
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6984403B2 (en) † 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects

Also Published As

Publication number Publication date
HRP950277B1 (en) 2002-06-30
US6068859A (en) 2000-05-30
RO114740B1 (ro) 1999-07-30
DK0758244T3 (da) 2002-02-11
CA2189658A1 (en) 1995-11-16
TNSN95051A1 (fr) 1996-02-06
EP0758244B2 (en) 2008-02-13
HUT77530A (hu) 1998-05-28
MX9605419A (es) 1997-12-31
US20020044965A1 (en) 2002-04-18
IS4282A (is) 1995-11-07
HRP950277A2 (en) 1997-10-31
NO964678D0 (no) 1996-11-05
IL131308A0 (en) 2001-01-28
SK143296A3 (en) 1998-07-08
MA23537A1 (fr) 1995-12-31
PE4796A1 (es) 1996-03-09
DZ1880A1 (fr) 2002-02-17
CZ324296A3 (cs) 1998-04-15
DE69524214D1 (de) 2002-01-10
JP2977907B2 (ja) 1999-11-15
WO1995030422A1 (en) 1995-11-16
LV11729B (en) 1997-08-20
DK0758244T4 (da) 2008-06-16
US7108865B2 (en) 2006-09-19
DE69524214T3 (de) 2008-05-15
NO964678L (no) 1997-01-06
UY23958A1 (es) 1995-10-31
NO315453B1 (no) 2003-09-08
ZA953627B (en) 1996-11-05
CA2189658C (en) 2000-10-31
CO4290346A1 (es) 1996-04-17
HU9603076D0 (en) 1997-01-28
DE69524214T2 (de) 2002-05-23
LV11729A (lv) 1997-04-20
PL179910B1 (pl) 2000-11-30
AU680356B2 (en) 1997-07-24
EP0758244A1 (en) 1997-02-19
RU2130311C1 (ru) 1999-05-20
CN1149831A (zh) 1997-05-14
KR100232297B1 (ko) 1999-12-01
AP548A (en) 1996-10-30
FI964452A (fi) 1996-11-05
BG100960A (en) 1997-08-29
KR970702727A (ko) 1997-06-10
NZ283160A (en) 1998-07-28
PL317106A1 (en) 1997-03-17
MY113059A (en) 2001-11-30
AP9500735A0 (en) 1995-04-30
IL131308A (en) 2001-07-24
FI964452A0 (fi) 1996-11-05
SK282854B6 (sk) 2002-12-03
AU2113195A (en) 1995-11-29
BR9501929A (pt) 1996-03-05
IL113516A (en) 2001-04-30
CZ292360B6 (cs) 2003-09-17
SI9520049A (en) 1997-12-31
JPH09505609A (ja) 1997-06-03
ATE209497T1 (de) 2001-12-15
IL113516A0 (en) 1995-07-31
CN1096862C (zh) 2002-12-25
EP0758244B1 (en) 2001-11-28
UA41995C2 (uk) 2001-10-15
PT758244E (pt) 2002-04-29
BG63152B1 (bg) 2001-05-31
ES2163504T5 (es) 2008-05-16
OA10320A (en) 1997-10-07
TW420616B (en) 2001-02-01

Similar Documents

Publication Publication Date Title
ES2163504T3 (es) Formas de dosificacion de liberacion controlada de azitromicina.
TR200102962T2 (tr) Yeni tedavi metodu.
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
DK1411932T3 (da) Kombinationsterapi med substituerede oxazolidinoner
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
ES2156150T3 (es) Combinacion terapeutica que contiene interferon.
NO20032027D0 (no) Effektive antitumorbehandlinger
CO4290359A1 (es) Metodo para tratar la alopecia androgenica con inhibidores 5-alfa-reductasa
MY138883A (en) Use of asiatic acid for treatment of cencer
SE9701161D0 (sv) New use I
ID24184A (id) Obat untuk perawatan disfungsi ereksi
YU42298A (sh) Upotreba olanzapina za pripremanje leka korisnog kod akutnog bola
NZ510153A (en) Tan-1057 derivatives with reduced toxicity and their use in medicaments for treating bacterial infections in humans and mammals
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
ES2101100T3 (es) Un producto para el tratamiento del cancer de higado y su procedimiento de manufactura.
AR015537A1 (es) Uso de brinzolamida para la manufactura de un medicamento para tratar o prevenir edema de retina.
ECSP951438A (es) Formas de dosificacion de liberacion controlada de azitromicina
MX9304878A (es) Uso de un azaspirano substituido en la fabricacion de un medicamento para utilizarse en el tratamiento de psoriasis.
GT199500023A (es) Formas de dosificacion de liberacion controlada azitromicina
ECSP951424A (es) Procedimiento para la administracion de azitromicina
ES2139382T3 (es) Sistema terapeutico percutaneo para compuestos de silatran.
NO984198L (no) FremgangsmÕte for behandling av aggresjon
SE9602145D0 (sv) New improved formulation for treatment of thromboembolism
MX9703975A (es) Nueva formulacion antitrombotica, proceso para su fabricacion y uso de la misma.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 758244

Country of ref document: ES